• Bonesupport’s third-quarter 2026 earnings per share before dilution more than doubled to SEK 1.41.
• Net sales rose 39% to SEK 408.8 million.
• US Medicare authorities confirmed qualifying CERAMENT G cases will receive the highest-reimbursing DRG assignments within their clinical categories.
• The complete supplemental data package for CERAMENT V was submitted to the FDA in September.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bonesupport Holding AB published the original content used to generate this news brief on October 22, 2026, and is solely responsible for the information contained therein.